Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT-HIT: Desirudin vs Argatroban in Suspected HIT
NCT00787332Phase 4Terminated
- Sponsor
- Canyon Pharmaceuticals
- Start
- Sep 2008
- Primary completion
- Dec 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of desirudin in heparin-induced thrombocytopenia (HIT) (2 arms), sponsored by Canyon Pharmaceuticals. Primary endpoint: New Thrombosis, Amputation, Death, Major and Minor Bleeding at 30 days. Started Sep 2008; status: terminated.
02
Drugs
desirudin
03
Conditions
heparin-induced thrombocytopenia (HIT)
Beyond the preview
Go deeper on NCT00787332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00787332.